Pemetrexed (Alimta)
Prognostic value of SUVpeak and prognostic nutritional index in patients with pleural mesothelioma treated with platinum-based chemotherapy
Translational Lung Cancer Research 2026 August 31 [Link] Yoshiki Kato, Kosuke Hashimoto, Hisao Imai, Kyoichi Kaira, Reina Ishii, Naohito Hashimoto, Ou Yamaguchi, Atsuto Mouri, Hiroshi Kagamu, Ichiei Kuji Abstract Background: Pleural mesothelioma (PM) is an aggressive malignancy with poor prognosis, and reliable prognostic biomarkers are needed to better inform clinical management. We retrospectively investigated the…
Read MoreEfficacy of Perioperative Platinum-Pemetrexed Chemotherapy Combined With Pleurectomy/Decortication for Pleural Mesothelioma
The Annals of Thoracic Surgery 2026 July 25 [Link] Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Ayumi Kuroda, Kyoshiro Takegahara, Takashi Kijima, Seiki Hasegawa, Soichiro Funaki Abstract Background: The optimal timing of chemotherapy in multimodal treatment of pleural mesothelioma remains unclear. This study evaluated the efficacy of adjuvant chemotherapy (AC) after neoadjuvant chemotherapy (NAC)…
Read MoreMaintenance pemetrexed after platinum pemetrexed chemotherapy and survival outcomes in malignant pleural mesothelioma in a multicenter real world study
Scientific Reports 2026 July 15 [Link] Okan Aydin, Zehra Sucuoglu Isleyen, Mert Erciyestepe, Ahmet Emin Ozturk, Sermin Dinc Sonusen, Tugay Atasever, Simay Cokgezer, Ebru Cicek, Ayse Gul Satman Durmaz, Lamia Seker Can, Gozde Balkaya Aykut, Tuba Baydas, Miray Aydogan, Seval Ay Ersoy, Muhammed Mustafa Atci, Kayhan Erturk Abstract Malignant pleural mesothelioma (MPM) is an aggressive…
Read MoreNavigating the Foggy Landscape of Epithelioid Peritoneal Mesothelioma: A Proposed Standardized Institutional Algorithm for Multimodal Management
Cancers 2026 June 30 [Link] Giorgio D’Annibale, Francesco Santullo, Lorenzo Barberis, Claudio Lodoli, Tommaso Partipilo, Giusi Giulia La Manna, Antonia Strippoli, Alexia Spring, Fabio Pacelli, Carlo Abatini Abstract Purpose: Diffuse malignant peritoneal mesothelioma is a rare disease requiring management in specialized referral centers. We report our institutional experience with epithelioid diffuse malignant peritoneal mesothelioma, focusing…
Read MoreLong-Term Disease Control With Second-Line Nivolumab Monotherapy in Malignant Pleural Mesothelioma: A Case Report
Cureus 2026 June 1 [Link] Shohei Otsuka, Kei Hiraoka, Nozomu Iwashiro Abstract Nivolumab is recommended as second-line therapy for malignant pleural mesothelioma (MPM); however, durable responses remain uncommon. In addition, combination immune checkpoint inhibitors are frequently limited by immune-related adverse events. A 72-year-old man with epithelioid MPM underwent extrapleural pneumonectomy followed by adjuvant chemotherapy with…
Read MoreCase Report: Tislelizumab combined with bevacizumab in the treatment of primary malignant pericardial mesothelioma
Frontiers in Oncology 2026 June 16 [Link] Zijuan Liu, Yating Yan, Caihong Jiang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is an exceedingly rare and highly malignant tumor that originates in the serosal layer of the pericardium. Currently, there are no specific guidelines for diagnosis and treatment in China and international countries for this disease,…
Read MoreOutcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Clinical Lung Cancer 2026 July 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract…
Read MoreOutcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Clinical Lung Cancer 2026 July [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Frank Griesinger, Martin Reck, Daniel C Christoph, Jonas Kuon, Nikolaj Frost, Christian Grohé, Martin Faehling, Felix C Saalfeld, Petra Hoffknecht, Jingting Luan, Julia Roeper, Paolo Chesi, Martin Kimmich, Till Olchers, Laura V Klotz, Inn Chung, Michael Thomas, Petros Christopoulos Abstract Background: There…
Read MoreCHIMERA: A Phase II Study of Neoadjuvant Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed Followed by Surgery and Adjuvant Pembrolizumab in Resectable Pleural Mesothelioma
Clinical Lung Cancer 2026 July [Link] Giulia Pasello, Daniela Scattolin, Eleonora Faccioli, Paolo Andrea Zucali, Giuseppe Marulli, Federica Grosso, Giovanni Luca Ceresoli, Marcello Tiseo, Alessandra Bearz, Fabiana Letizia Cecere, Luana Calabrò, Francesco Callegarin, Paola Del Bianco, Gian Luca De Salvo, Federica Pezzuto, Fiorella Calabrese, Valentina Guarneri, Andrea Dell’Amore, Federico Rea Abstract Pleural mesothelioma (PM) is…
Read MoreThe Role of EZH2 ın Malıgnant Pleural Mesothelıoma and Beyond: Current Practıce and Future Perspectıves
Current Oncology Reports 2026 June 8 [Link] Mehmet Kucukoner, Tarik Demir, Abduljalil Mohammed Alsubaie, Ulas Alabalik, Aisha K Ibrahim, Mariaelena Pierobon, Lance Liotta Abstract Purpose of review: Malignant pleural mesothelioma (MPM) remains a rare but highly aggressive malignancy with limited treatment options and poor prognosis. For nearly twenty years, platinum-pemetrexed chemotherapy has persisted as the…
Read More
Skip to content